Page last updated: 2024-08-23

silybin and pf-06463922

silybin has been researched along with pf-06463922 in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	1 (100.00)	2.80

Authors

Authors	Studies
Bosch-Barrera, J; Cuyàs, E; Encinar, JA; Fernández-Arroyo, S; Joven, J; Menendez, JA; Verdura, S	1

Other Studies

1 other study(ies) available for silybin and pf-06463922

Article	Year
Silibinin Suppresses the Hyperlipidemic Effects of the ALK-Tyrosine Kinase Inhibitor Lorlatinib in Hepatic Cells. International journal of molecular sciences, 2022, Sep-01, Volume: 23, Issue:17 Topics: Aminopyridines; Anaplastic Lymphoma Kinase; Carcinoma, Non-Small-Cell Lung; Cytochrome P-450 CYP3A; Hepatocytes; Humans; Lactams; Lactams, Macrocyclic; Lipids; Lung Neoplasms; Protein Kinase Inhibitors; Pyrazoles; Silybin; Tandem Mass Spectrometry; Triglycerides	2022

Article

Year

Silibinin Suppresses the Hyperlipidemic Effects of the ALK-Tyrosine Kinase Inhibitor Lorlatinib in Hepatic Cells.

International journal of molecular sciences, 2022, Sep-01, Volume: 23, Issue:17

Topics: Aminopyridines; Anaplastic Lymphoma Kinase; Carcinoma, Non-Small-Cell Lung; Cytochrome P-450 CYP3A; Hepatocytes; Humans; Lactams; Lactams, Macrocyclic; Lipids; Lung Neoplasms; Protein Kinase Inhibitors; Pyrazoles; Silybin; Tandem Mass Spectrometry; Triglycerides

2022